RxDoctor Payments Data

Daisy Borroto, MD

Neurology · Miami, FLNPI 1932341104

Payments from drug & device makers

$1,893in general payments, 2019–2025

Across 100 payments — averaging $18.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$378
  • AbbVie$326
  • Teva Pharmaceuticals USA, Inc.$193
  • Novartis$180
  • Johnson & Johnson$172
  • Argenx US, Inc.$122
  • plus $522 from 13 others

What the payments were for

  • Food & beverage$1,81596%
  • Education$784%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,893 in reported general payments places this provider in the 45th percentile of 1,434 neurology providers in Florida.

See all neurology providers in Florida

Medicare billing

Part B allowed, 2024
$74,146
Medicare patients
130
Services billed
395

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Ajovy AutoinjectorFremanezumab-Vfrm66$52,592
RytaryCarbidopa/Levodopa117$49,273
Lacosamide86$27,780
BotoxOnabotulinumtoxina29$24,210
Memantine Hcl ErMemantine Hcl130$23,819
Galantamine Hbr512$22,333
GocovriAmantadine Hcl13$21,577
NamzaricMemantine Hcl/Donepezil Hcl24$13,731
Pregabalin353$10,144
Rasagiline Mesylate42$8,460
Carbidopa-LevodopaCarbidopa/Levodopa540$7,703
Rivastigmine39$7,327
Entacapone30$4,904
Carbamazepine ErCarbamazepine55$4,519
Donepezil Hcl535$3,779

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Amneal Pharmaceuticals LLCRytary, Mycophenolate Mofetil, Pyridostigmine Bromide$67$52,095168 claims
AbbVieBotox, Namzaric$326$37,94053 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 1,434 neurology providers in Florida.

Other neurology in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →